
OUTCOME OF THE TWENTY-SECOND ANNUAL GENERAL MEETING HELD ON NOVEMBER 26, 2020

The Board of Directors of Vicplas International Ltd (the **Company**) is pleased to announce, pursuant to Rule 704(16) of the Listing Manual of the Singapore Exchange Securities Trading Limited (the **SGX-ST**), that at the Twenty-Second Annual General Meeting of the Company held on November 26, 2020 (the **AGM**), all resolutions set out in the Notice of AGM dated November 4, 2020 were passed by the Company's shareholders by way of poll vote.

(a) Slide Presentations

Before the meeting proceeded with the business of the AGM, slide presentations from the Pipes and Pipe Fitting Segment and the Medical Devices Segment were presented to the shareholders and copies of these are attached hereto.

(b) Breakdown of all valid votes cast at the AGM

Pursuant to Rule 704(16)(a) of the Listing Manual of the SGX-ST, the breakdown of all valid votes cast on each of the resolutions put to the vote at the AGM are set out below:

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of Shares	As a percentage of total number of votes for the resolution (%)	Number of Shares	As a percentage of total number of votes against the resolution (%)
Ordinary Business					
Ordinary Resolution 1 To receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the year ended July 31, 2020 and the Auditors' Report thereon.	341,344,551	341,344,551	100.00%	0	0.00%
Ordinary Resolution 2 To declare a final (one-tier tax exempt) dividend of S\$0.00375 per share for the year ended July 31, 2020.	341,344,551	341,344,551	100.00%	0	0.00%
Ordinary Resolution 3 To approve Directors' fees of S\$250,644.00 for the year ended July 31, 2020.	341,344,551	341,344,551	100.00%	0	0.00%

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of Shares	As a percentage of total number of votes for the resolution (%)	Number of Shares	As a percentage of total number of votes against the resolution (%)
Ordinary Resolution 4 To re-elect Mrs. Jane Rose Philomene Gaines-Cooper as a Director pursuant to Article 115 of the Company's Constitution.	341,344,551	341,344,551	100.00%	0	0.00%
Ordinary Resolution 5 To re-elect Mr. Christopher Paul Lee as a Director pursuant to Article 115 of the Company's Constitution.	338,344,551	338,344,551	100.00%	0	0.00%
Ordinary Resolution 6 To re-appoint Deloitte & Touche LLP as Auditor and to authorise the Directors to fix their remuneration.	341,344,551	341,344,551	100.00%	0	0.00%
Special Business					
Ordinary Resolution 7 To authorise the Directors to issue additional shares and convertible instruments.	341,344,551	341,144,551	99.94%	200,000	0.06%
Ordinary Resolution 8 To approve the renewal of the Shareholders' Mandate for interested person transactions.	52,491,810	52,491,810	100.00%	0	0.00%
Ordinary Resolution 9 To approve the renewal of the Share Purchase Mandate.	341,344,551	341,344,551	100.00%	0	0.00%

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of Shares	As a percentage of total number of votes for the resolution (%)	Number of Shares	As a percentage of total number of votes against the resolution (%)
Ordinary Resolution 10 To authorise the issuance of new shares pursuant to the Vicplas International Ltd Scrip Dividend Scheme.	341,344,551	341,344,551	100.00%	0	0.00%

(c) Details of parties who are required to abstain from voting on any resolutions

Pursuant to Rule 704(16)(b) of the Listing Manual of the SGX-ST, the details of parties who are required to abstain from voting on the resolutions tabled at the AGM are set out below.

Venner Capital S.A., its subsidiaries and associates, being interested persons (as described in paragraph 4.1 of the Appendix 1 to the Circular to Shareholders dated November 4, 2020) in relation to the Shareholders' Mandate for interested person transactions, including proxies of such shareholders, holding in aggregate 288,852,441 ordinary shares in the capital of the Company, have accordingly abstained from voting at the AGM in respect of Resolution 8.

(d) Name of firm appointed as scrutineer

Finova BPO Pte Ltd was appointed as the scrutineer for the AGM.

(e) Re-election of Directors

Mrs. Jane Rose Philomene Gaines-Cooper, who was re-elected as a Non-Independent and Non-Executive Director of the Company, remains as a member of Audit and Risk Committee, the Nominating Committee, the Remuneration Committee and the Strategy Committee of the Company.

Mr. Christopher Paul Lee, who was re-elected as a Non-Independent and Non-Executive Director of the Company, remains as Chairman of the Strategy Committee of the Company.

(f) 'Live' Q& A session during the AGM

No questions were received from shareholders during the 'live' Q&A session.

BY ORDER OF THE BOARD

Cheng Liang
Group Chief Executive Officer
November 26, 2020

Vicplas International

Presentation at Annual General Meeting
on 26 November 2020



02

Pipes & Pipe Fittings

Jay Cheng
Group Operations Director





About Us

We manufacture and distribute uPVC piping systems for:

- Waste and potable water
- Telecommunications
- Electrical and power lines



1016 9277

Regional Footprint

Malaysia

Sales
Manufacturing

Singapore

Global HQ
Sales
Manufacturing

 **Vicplas Holdings Pte Ltd, Singapore**

 : 89

 **Rimplas Industries Sdn Bhd, Malaysia**

 : 64

Competitive Strengths

Total Solutions

We differentiate ourselves as a total solutions provider by going beyond the basics to offer more value.



Integrated Manufacturing

We are a fully integrated producer equipped with injection moulding, extrusion and tooling capabilities.



Quality

Internal audits and external certifications ensure our products meet regulatory requirements.



Efficiency

Investing in new technologies to enhance operational and manufacturing efficiencies.



Innovation

We hone our skills and manufacturing capabilities in plastics processing through a dedicated R&D team.






Sustainability

We adopt best practices in sustainable resource utilisation, and by making products that last.



Core Capabilities



Testing and Certification Partners

ooo

Vicplas' products are all certified by international testing bodies to meet the highest standards of product quality.





Business Updates




- In FY2020, most construction projects in Singapore suffered a four-month stoppage due to government's efforts to contain Covid-19
- Resulting project delays and deadline extensions impacted our performance in FY2020
- Expect a slow recovery in 1H2021 as construction projects in Singapore re-commence gradually
- Continue to operate prudently and improve processes to enhance manufacturing efficiencies
- Focus in FY2021 on new private and public residential homes e.g. HDB's Home Improvement Program; civil engineering projects; and product expansion e.g. hydro-agriculture pipes/channels

ooo

Construction projects

- Commercial Buildings
- Shopping Malls
- Industrial Buildings
- Residential Homes
- Schools
- Hospitals
- Civil Engineering





The Vicplas hydro-agriculture pipes / channels are currently being developed for vegetable farming needs in Singapore

ooo



03

Medical Devices

Walter Tarca
President



Global Presence



Global HQ, Technical Design Centre & Manufacturing Joo Koon, Singapore	Business Development (Asia) Shanghai, China	Business Development (America and Europe) Connecticut, USA, Kington, UK	Manufacturing (Xiamen, China) Xiamen Export Processing Zone	Manufacturing (Changzhou, China) Wujin Economic Zone	Manufacturing (Kington, UK) Hatton Gardens, Kington, Herefordshire HR5 3RB
--	---	---	---	--	--

Global Presence

4 Manufacturing Sites ~ 950+ employees

- Singapore – Corporate HQ (7,410 m²)
- Xiamen – 7,000 m²
- Changzhou – 7,024 m²
- Kington – 3,000 m²

Commercial Offices

- Singapore
- Connecticut, USA
- Shanghai, China
- Kington, UK



Singapore, HQ



Changzhou, China




Xiamen, China




Kington, UK

Value Proposition




Total Solution to Protect the Product Owner's Premium brand


Our Capabilities – Concept to Commercialization



Our Medical Device Portfolio



Injection Molded Medical Components



- **Micro-Molding**
- **Insert Molding** (plastics & metals)
- **Co-Injection**
- **Multi-Shot Molding**
- **Unscrew Molding**
- **Tooling Capabilities**
 - Stack Mold
 - Spin-Stack Mold
 - In-Mold Assembly

Components: Extrusion Medical Tubing

- **Multi-lumen tubes**
- **Braided tubes**
- **Co Extrusion**
- **Multi Color/Layer Extrusion**
- **Small bore tubes**
(catheters)
- **Specialty Tubes** (Radio Opaque Additives added tube)



Complete Devices: High Pressure Inflation Device

Injection | Secondary Process | Assembly | Packaging | Sterilization

Secondary Processes Involved

- Assembly
- Pad Printing
- Adhesive/Solvent Bonding
- UV Curing
- Tray sealing & Packaging



Complete Devices: Safety Wing Infusion Set

Injection | Secondary Process | Assembly | Packaging



Assembly Automation Line in Class 7
(10k) Assembly Cleanroom

Complete Devices: Infusion Set

Injection | Extrusion | Assembly | Packaging | Sterilization




Complete Devices: Endotracheal Tube

Injection | Extrusion | Assembly | Packaging | Sterilization


ETT

A **Endotracheal tube** is a catheter that is inserted into the trachea for the primary purpose of establishing and maintaining a patient airway and to ensure the adequate exchange of oxygen and carbon dioxide.



Complete Devices: Jejunal & Naso-gastric Feeding Tube

Product Development | Injection | Extrusion | Assembly | Packaging | Sterilization



Secondary Processes

- Assembly
- Hydrophilic Coating
- Adhesive/Solvent Bonding
- UV Curing
- Tyvek Pouch Packaging

Entering the Orthodontics Space



FULL DEVICE – SCANBOX

Injection | Assembly | Packaging



Beyond Manufacturing Services

Nasopharyngeal Swabs



Nasopharyngeal Swabs by Forefront Medical

Clinically tested and proven effectiveness

Class A device registered with HSA, USFDA & CE



Patented tip design

Made with biocompatible nylon

Flexible neck ensures ease of use and improved patient comfort

* Marketing has just commenced. No overseas sales as yet.

Our Strategic Intent



To become a leading Global medical device manufacturing partner by delivering value to our customers through innovative solutions and excellence in execution

To grow we will focus on:

Sustainable
Customer &
Portfolio
Growth

Operational
Excellence

Innovation

High
Performance
Team

Update on Covid-19

Current Situation

- Both China plants were closed for more than 40 days during Feb/Mar 2020 - now operating per normal
- Disruption caused in FY2020 with customer order postponement, supply chain disruption and labour hiring issues
- Despite disruption in FY2020, sales grew 36% and segmental profit grew 180%
- Forefront is not reliant on Covid-19 for growth and our strategy calls for sustainable growth in Sales and operational performance
- In FY2020 we commenced work on some Covid-19 projects for customers, mostly in Singapore

Outlook

- Refurbishment of Singapore clean rooms creates more opportunities for Singapore plant
- Today we are manufacturing in Singapore for our customers 3D Nasal Swabs, Injection Molded Nasal Swabs and Saliva Based Covid-19 Test Kits to help Singapore fight against Covid-19
- Backlog exists to catch up demand on postponed elective surgeries for our customer base

FY2020 Improvements

Broadened & Deepened Customer Portfolio

- Sustainable business growth in sales and operational performance despite Covid-19
- Moved into New Revenue streams such as IVD, Electromechanical Devices, Specialty tubing
- More projects and opportunities for Singapore plant
- Acquisition of Arrow Medical in UK

Improved Operational Efficiency

- Utilisation & efficiency improvement in all plants
- Refurbishment to Singapore clean rooms
- Continued investment in automation

High Employee Engagement

- Investment in Medtech talent pool to drive new revenue streams
- Engaged & tenured team delivering quality and reliability of supply

Forefront Medical in the NEWS

Diversifying operations and talent pool helps medtech firm find new income streams amid Covid-19

By Kelly Ng
kellyng@sph.com.sg
@KellyNgBT
Singapore

EAGER to tap Singapore's growing reputation for healthcare innovation and to spread out risks amidst uncertainty elsewhere in the world, homegrown medtech firm Forefront Medical Technologies (FMT) made a concerted effort two years ago to diversify its product and service offerings.

This involved pumping in S\$1.5 million to refurbish and expand its cleanrooms, building up automation capabilities, and diversifying its talent pool.

Today, the firm – which started its Singapore plant in 2000 and was originally focused on making just one specific product



FMT president Walter Tarca says the firm has been able to use its resources to fulfil customers' orders promptly.

for anesthesia and surgery – finds itself pivoting into the diagnostics space, in line with demand amidst the Covid-19 pandemic.

FMT, which was highlighted by Deputy Prime Minister Heng Swee Keat as a firm that has benefited from early transformation, has snagged four projects centred on Covid-19-related products.

One of them involves producing 3D-printed nasal swabs, its president Walter Tarca told *The Business Times*.

"In this time of Covid-19, everybody wants things done yesterday. In this regard, we have been able to make use of readily available space and our engineering people to fulfill customers' orders promptly," he said.

Mr Tarca said his team saw the opportunity to widen the range of products manufactured in its Singapore plant after much

of its low-cost operations were relocated to China. The firm set up two plants in China, in 2007 and 2013.

"Singapore is seen by our customers, many of them multinational firms, as a very safe place. Customers value its integrity and reputation for innovation.

And with the growing uncertainty between China and the United States, many preferred to have their operations based in Singapore," he said.

In preparing to take up new projects here, FMT invested in cleaning room capacity, upskilled its engineers, and also hired employees who could perform functions in other phases of its value chain.

It also acquired product design and development firm XentIQ, which enhanced its vertical integration.

Continued on Page 5

Medtech firm diversifies to find new income streams

Continued from Page 4

A year ago, FMT also set up a technical centre, which houses five employees tasked to develop and enhance the firm's capabilities in serving new market segments.

"Diversification is important to de-risk a company. Good companies do not put all their eggs in the same basket," Mr Tarca said.

And its investment seems to have paid off. According to Mr Tarca, the company raked in S\$45 million in sales revenue at the end of its financial year in July 2019, compared to S\$31.9 million in July 2018.

Its six-month sales revenue in January this year stood at S\$29.8 million, compared to S\$17.8 million in January 2019.

Because FMT is involved in manufacturing products that help in the fight against the ongoing pandemic, it has been able to continue operations during Singapore's partial lockdown.

In the coming years, FMT plans to expand its presence in Singapore's medtech scene, eyeing in particular the production of in vitro diagnostics, which Mr Tarca said is a sub-segment that has not yet seen many players here.

The firm is also looking at widening its use of 3D printing and automation, he added.

"Singapore is very highly regarded as a centre of excellence in technology. It makes sense for us to explore innovations here that can help us offer products at a better price and value for customers," he said.



FMT is working on four projects involving Covid-19-related products. PHOTO: FOREFRONT MEDICAL TECHNOLOGIES

Article on Straits Times



Plant Visit by Deputy Prime Minister Heng Swee Keat on 19th August 2020

Parliament

Firm's \$1.5m investment to refurbish facility pays off



Employees assembling medical devices in a clean room in Forefront Medical's facility in Singapore. Among the five projects related to the coronavirus it has secured recently are test kit and nasal swab production. PHOTO: FOREFRONT MEDICAL

PUBLISHED 4 HOURS AGO



Choo Yun Ting

Singapore-headquartered precision engineering firm Forefront Medical embarked on its transformation journey some 18 months ago, putting in \$1.5 million to refurbish the clean rooms at its facility here.

"The refurbishment was not for any specific projects that were (in the pipeline), but was part of our efforts to attract more projects to the facility here in Singapore," Forefront Medical president Walter Tarca told *The Straits Times*.

The firm also expanded its automation capabilities and hired 11 people with medical technology expertise. These investments have been paying off amid the global Covid-19 pandemic, positioning the company, which manufactures products for the medical industry, to "catch the wave".

Among the five coronavirus-related projects it has secured recently are test kit and nasal swab production, Mr Tarca said.

While the company has caught the upswing in demand for medical products amid the virus outbreak, the investments that it has made are particularly significant because they will sustain the firm for the long term, he said, noting that the made-in-Singapore brand is one which multinational clients appreciate and value.

Article on Business Times

FY2021 Priorities

Sustainable Sales & Operational Performance Growth

- Leverage long term relationships for further collaborative projects
- Ramp up new Revenue streams IVD, Electronic Devices, Speciality tubing
- Drive local presence to improve Europe & UK opportunities
- Offer additional manufacturing locations i.e. Singapore, UK, explore new 5th plant

Drive Operational Excellence Programs

- Improve our end to end operational capabilities to provide greater value to customers
- Leverage automation efficiencies to further improve margins

Expand Collaborative Innovation

- Continue to roll out technology road map to increase our addressable market opportunities
- Drive Forefront Technical Centre to attain new value added capabilities and revenue streams

Invest in our People

- Continue to improve our Medtech talent pool through training and recruitment
- Build leadership team to manage growth



Thank you